Table 1 (abstract A14).
Characteristics of Physician Management of JSpA Patients (n=60)
| N (%) | |
|---|---|
| Practice Location | |
| Academic | 55 (91) |
| Private | 4 (7) |
| Years in practice | |
| <5 years | 18 (30) |
| 5-10 years | 17 (28) |
| 11-15 years | 9 (15) |
| > 15 years | 16 (27) |
| Training | |
| Pediatric Rheumatologist | 56 (93) |
| Med/Peds Rheumatologist | 3 (5) |
| Other | 1 (2) |
| Number of JSpA patients seen annually | |
| < 5 patients | 5 (8) |
| 5-10 patients | 16 (27) |
| >10 patients | 39 (65) |
| Duration before deeming treatment failure | |
| 2 months | 4 (7) |
| 3 months | 36 (60) |
| 6 months | 14 (23) |
| Have JSpA patients who failed TNFi therapy in last 2 yrs | 38 (63) |
| Have switched back to same TNFi after failing | 10 (17) |
| Reasons for change anti-TNF therapy: | |
| Secondary non-response | 43 (72) |
| Primary non-response | 35 (58) |
| Intolerance | 29 (48) |
| Concomitant disease | 28 (47) |
| Chronic pain | 15 (25) |
| Reasons for primary non-response | |
| Arthritis (Sacroiliac joints) | 27 (45) |
| Arthritis (peripheral) | 16 (27) |
| Enthesitis | 16 (27) |
| Pain | 2 (1) |
| Number of anti-TNF agents (total) tried before switching to another class | |
| 1 | 1 (1.5) |
| 2 | 37 (62) |
| 3 | 21(35) |
| >3 | 1 (1.5) |
| Other medications used after TNFi failure | |
| Abatacept | 24 (40) |
| Tocilizumab | 21 (35) |
| Ustekinumab | 17 (28) |
| Secukinumab | 16 (27) |
| Tofacitinib | 8 (13) |
| Rituximab | 2 (3) |
| Other: Apremilast (1), Methotrexate (1), Steroids (1) | |